45 ms·

Not even cost plus? Not sure how that works, from the viewpoint of economic incentives.

• ulfw 8mo ago
  It's literally free data for efficacy / later sales.
  • vibrio 8mo ago
    So charging patients/insurance companies at cost to fund the clinical studies?
    • DennisP 8mo ago
      Clinical studies today are funded entirely by the pharma companies, keep that. Selling at cost of production would be something extra, for patients who want the drugs but aren't enrolled in an actual study. The company doesn't get solid data it can use for regulatory approval, so making them donate the drugs in that case seems excessive. A downside would be that for drugs that don't cost much to produce, patients might be less willing to enroll in the studies, given the chance of getting a placebo. That could be handled by shutting down the informal access while the study is enrolled, for anyone who's eligible. I'm sure there are other wrinkles that would need to be considered too.
      • vibrio 8mo ago
        Put this way, this seems reasonable. Beyond cell therapy, I don't thin the cost of drug is the motivation for not making it more freely available. 'Misuse' leading to potential liability or unjustified bad outcomes, along with some regulatory burden seems like the issue.